The threat of antimicrobial resistance in developing countries: Causes and control strategies

Antimicrobial Resistance and Infection Control

Volumn 6, Issue 1, 2017, Pages

  Ayukekbong, James A ^a,d   Ntemgwa, Michel ^b   Atabe, Andrew N ^c  

^a Section for Clinical Microbiology   (Cameroon)

^b Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d METABIOTA INC   (United States)

Author keywords

Antimicrobial therapy; Developing countries; Microorganisms; Resistance

Indexed keywords

CHLOROQUINE; COUNTERFEIT DRUG; DIPHTHERIA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; SMALLPOX VACCINE;

ANIMAL WELFARE; ANTIBIOTIC RESISTANCE; BREEDING; CLINICAL PRACTICE; CROWDING (AREA); DEVELOPING COUNTRY; DIPHTHERIA; DRUG CONTROL; DRUG MARKETING; DRUG QUALITY; DRUG STORAGE; ENVIRONMENTAL SANITATION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH PROMOTION; HELP SEEKING BEHAVIOR; HUMAN; HYGIENE; INFECTION PREVENTION; MEASLES; MEDICATION COMPLIANCE; MULTIDRUG RESISTANCE; MUMPS; NONHUMAN; PERTUSSIS; POLIOMYELITIS; POVERTY; PRESCRIPTION; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; RUBELLA; SMALLPOX; VACCINATION; VETERINARY MEDICINE;

EID: 85019237541     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/s13756-017-0208-x     Document Type: Review

References (76)

1. Byarugaba DK. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents. 2004;24:105-10.
2. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057-98.
3. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect. Dis. 2005;5:568-80.
4. Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect. Dis. 2005;5:481-93.
5. Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ. 1998;317:647-50.
6. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:18-27.
7. Kunin CM. Resistance to antimicrobial drugs--a worldwide calamity. Ann Intern Med. 1993;118:557-61.
8. Fluit AC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev. 2001;14:836-871, table of contents.
9. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8:423-35.
10. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19:1-24.
11. Quick J, Bremer K. Quality control of essential drugs. Lancet Lond Engl. 1997;350:1106.
12. Lansang MA, Lucas-Aquino R, Tupasi TE, Mina VS, Salazar LS, Juban N, Limjoco TT, Nisperos LE, Kunin CM. Purchase of antibiotics without prescription in Manalia, the Philippines. Inappropriate choices and doses. J Clin Epidemiol. 1990;43:61-7.
13. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis. 2007;13:1640-6.
14. Goel P, Ross-Degnan D, Berman P, Soumerai S. Retail pharmacies in developing countries: a behavior and intervention framework. Soc Sci Med. 1996;42:1155-61.
15. Kwena Z, Sharma A, Wamae N, Muga C, Bukusi E. Provider characteristics among staff providing care to sexually transmitted infection self-medicating patients in retail pharmacies in Kibera slum, Nairobi. Kenya Sex Transm Dis. 2008;35:480-3.
16. Basco LK. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. AmJTrop Med Hyg. 2004;70:245-50.
17. Winstanley P, Ward S, Snow R, Breckenridge A. Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev. 2004;17:612-37.
18. Okeke IN, Lamikanra A. Quality and bioavailability of ampicillin capsules dispensed in a Nigerian semi-urban community. Afr J Med Med Sci. 2001;30:47-51.
19. Risha PG, Shewiyo D, Msami A, Masuki G, Vergote G, Vervaet C, et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health TM IH. 2002;7:701-7.
20. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2:e100.
21. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother. 2007;60:214-36.
22. Usluer G, Ozgunes I, Leblebicioglu H, Turkish antibiotic utilization study group. A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann Clin Microbiol Antimicrob. 2005;4:16.
23. Saleh N, Awada S, Awwad R, Jibai S, Arfoul C, Zaiter L, et al. Evaluation of antibiotic prescription in the Lebanese community: a pilot study. Infect Ecol Epidemiol. 2015;5:27094.
24. Neu HC. The crisis in antibiotic resistance. Science. 1992;257:1064-73.
25. Calva J, Bojalil R. Antibiotic use in a periurban community in Mexico: a household and drugstore survey. Soc Sci Med. 1996;42:1121-8.
26. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy. 2009;90:32-6.
27. Malfertheiner P. Compliance, adverse events and antibiotic resistance in helicobacter pylori treatment. Scand J Gastroenterol. 1993;28:34-7.
28. Collignon P, Wegener HC, Braam P, Butler CD. The routine use of antibiotics to promote animal growth does little to benefit protein undernutrition in the developing world. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc Am. 2005;41:1007-13.
29. Petersen A, Andersen JS, Kaewmak T, Somsiri T, Dalsgaard A. Impact of integrated fish farming on antimicrobial resistance in a pond environment. Appl Environ Microbiol. 2002;68:6036-42.
30. Vidaver AK. Uses of antimicrobials in plant agriculture. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002;34(Suppl 3):S107-10.
31. Witte W. Medical consequences of antibiotic use in agriculture. Science. 1998;279:996-7.
32. Food and Agriculture Organization. Drivers, dynamics and epidemiology of antimicrobial resistance in animal production. [Internet]. FAO; 2016 [cited 2017 Jan 4]. Available from: http://www.fao.org/3/a-i6209e.pdf
33. Aarestrup F. Sustainable farming: get pigs off antibiotics. Nature. 2012;486:465-6.
34. Mitema ES, Kikuvi GM, Wegener HC, Stohr K. An assessment of antimicrobial consumption in food producing animals in Kenya. J Vet Pharmacol Ther. 2001;24:385-90.
35. Mezali L, Hamdi TM. Prevalence and antimicrobial resistance of Salmonella isolated from meat and meat products in Algiers (Algeria). Foodborne Pathog Dis. 2012;9:522-9.
36. Addis Z, Kebede N, Sisay Z, Alemayehu H, Wubetie A, Kassa T. Prevalence and antimicrobial resistance of Salmonella isolated from lactating cows and in contact humans in dairy farms of Addis Ababa: a cross sectional study. BMC Infect. Dis. [Internet]. 2011 [cited 2017 Jan 24];11. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-222.
37. Fortini D, Fashae K, García-Fernández A, Villa L, Carattoli A. Plasmid-mediated quinolone resistance and β-lactamases in Escherichia coli from healthy animals from Nigeria. J Antimicrob Chemother. 2011;66:1269-72.
38. Kikuvi GM, Ombui JN, Mitema ES. Serotypes and antimicrobial resistance profiles of Salmonella isolates from pigs at slaughter in Kenya. J Infect Dev Ctries. 2010;4:243-8.
39. Doyle ME. Multidrug-resistant pathogens in the food supply. Foodborne Pathog Dis. 2015;12:261-79.
40. Simango C, Rukure G. Potential sources of campylobacter species in the homes of farmworkers in Zimbabwe. J Trop Med Hyg. 1991;94:388-92.
41. Roess AA, Winch PJ, Akhter A, Afroz D, Ali NA, Shah R, et al. Household animal and human medicine use and animal husbandry practices in rural Bangladesh: risk factors for emerging Zoonotic disease and antibiotic resistance. Zoonoses Public Health. 2015;62:569-78.
42. Cabello FC. Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol. 2006;8:1137-44.
43. Brandenburg K, Schürholz T. Lack of new antiinfective agents: passing into the pre-antibiotic age? World J Biol Chem. 2015;6:71-7.
44. Smith MA, Garbharran H, Edwards MJ, O'Hara-Murdock P. Health promotion and disease prevention through sanitation education in south African Zulu and Xhosa women. J Transcult Nurs Off J Transcult Nurs Soc. 2004;15:62-8.
45. Hinman AR, Orenstein WA. Adult immunization: what can we learn from the childhood immunization program? Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;44:1532-5.
46. Iglehart JK. Health policy report. The centers for disease control. N Engl J Med. 1983;308:604-8.
47. Robinson CA, Bart KJ. Disease prevention through immunization: the beginning of health care reform. Public Health Rep. 1993;108:417-8.
48. van Panhuis WG, Grefenstette J, Jung SY, Chok NS, Cross A, Eng H, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med. 2013;369:2152-8.
49. López EL, Glatstein E, Ezcurra GC, Iacono M, Teplitz E, Garnero AV, et al. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina. J Pediatr Infect Dis Soc. 2017. doi: 10.1093/jpids/piw089.
50. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997;5:268-71.
51. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. J Inf Secur. 1998;36:5-15.
52. Mathur MD, Vidhani S, Mehndiratta PL. Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India. 2003;51:593-6.
53. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol IJMM. 2006;296:149-61.
54. Williams P. Quorum sensing, communication and cross-kingdom signalling in the bacterial world. Microbiol Read Engl. 2007;153:3923-38.
55. Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol. 2005;21:319-46.
56. Brandt LJ. Fecal transplantation for the treatment of Clostridium Difficile infection. Gastroenterol Hepatol. 2012;8:191-4.
57. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136:2015-31.
58. Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, Nieuwdorp M. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol. 2013;27:127-37.
59. Borody TJ, Brandt LJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: a new standard treatment option for Clostridium Difficile infection. Expert Rev Anti-Infect Ther. 2013;11:447-9.
60. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep. 2013;15:337.
61. Bhutta TI, Balchin C. Assessing the impact of a regulatory intervention in Pakistan. Soc Sci Med. 1996;42:1195-202.
62. Blakely JT-M, Sinkowitz-Cochran RL, Jarvis WR. Infectious diseases physicians' preferences for continuing medical education on antimicrobial resistance and other general topics. Infect Control Hosp Epidemiol. 2006;27:873-5.
63. Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries. J Int AIDS Soc. 2008;11:2.
64. Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. The impact of the journalist-to-journalist program on worldwide HIV awareness. AIDS Lond Engl. 2008;22:1687-8.
65. World Health Organization. Global action plan on antimicrobial resistance [Internet]. 2015 [cited 2017 Jan 4]. Available from: http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1.
66. Government of Canada. Federal action plan on antimicrobial resistance and use in Canada (building on the federal framework for action). Accessed [Internet]. 2015 [cited 2017 Jan 4]. Available from: http://healthycanadians.gc.ca/alt/pdf/publications/drugs-products-medicaments-produits/antibiotic-resistance-antibiotique/action-plan-daction-eng.pdf.
67. Government of the United Kingdom. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018 [Internet]. 2013 [cited 2017 Jan 4]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf.
68. Government of the United States. National strategy for combating antibiotic-resistant bacteria. [Internet]. 2015 [cited 2017 Jan 4]. Available from: https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf.
69. World Health Organization. WHO report finds systems to combat antibiotic resistance lacking [Internet]. 2015 [cited 2017 Jan 4]. Available from: http://www.who.int/mediacentre/news/releases/2015/antibiotic-resistance-lacking/en/.
70. World Health Organization. Additional global, regional and national strategies and plans to address antimicrobial resistance [Internet]. 2014 [cited 2016 Dec 3]. Available from: http://www.cddep.org/garp/home.
71. Africa Society for Laboratory Medicine. ASLM2016 helps to answer United Nations call to tackle threat of antimicrobial resistance. [Internet]. 2016 [cited 2017 Jan 4]. Available from: http://aslm2016.org/aslm2016-helps-to-answer-united-nations-call-to-tackle-threat-of-antimicrobial-resistance/.
72. Tollefson L. Developing new regulatory approaches to antimicrobial safety. J Vet Med B Infect Dis Vet Public Health. 2004;51:415-8.
73. WHO. Global action plan on antimicrobial resistance. 2015 [cited 2017 Jan 5]; Available from: http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1.
74. WHO. Additional global, regional and national strategies and plans to address antimicrobial resistance. 2014 [cited 2016 Dec 4]; Available from: http://www.who.int/drugresistance/global_action_plan/General_and_national_plans_amr_Dec_2014.pdf.
75. Dua V, Kunin CM, White LV. The use of antimicrobial drugs in Nagpur, India. A window on medical care in a developing country. Soc Sci Med. 1994;38:717-24.
76. NEPAD. African Medicines Regulatory Harmonization (AMRH). 2016 [cited 2017 Jan 5]; Available from: http://www.nepad.org/content/african-medicines-regulatory-harmonisation-armh-programs?qt-programme_page=1.